Drug profile · INN
pentolinium tartrate
ANSOLYSEN
pentolinium tartrate (ANSOLYSEN) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — pentolinium tartrate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pentolinium tartrate (ANSOLYSEN) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Neuronal acetylcholine receptor; alpha3/beta4 antagonist
Primary target: Neuronal acetylcholine receptor; alpha3/beta4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pentolinium tartrate?
pentolinium tartrate (ANSOLYSEN) is a neuronal acetylcholine receptor; alpha3/beta4 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for pentolinium tartrate?
ANSOLYSEN is a marketed brand name for pentolinium tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pentolinium tartrate?
pentolinium tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.